
    
      Patients receive nivolumab intravenously (IV) over 30 minutes on day 1. Treatment repeats
      every 2 weeks for up to 12 courses and then every 4 weeks for additional 8 courses in the
      absence of disease progression or unacceptable toxicity. Patients also receive ipilimumab IV
      over 60 minutes on day 1. Treatment repeats every 6 weeks for up to 4 courses in the absence
      of disease progression or unacceptable toxicity. Beginning week 3, patients undergo 3
      fractions of stereotactic body radiation therapy every other day in the absence of disease
      progression or unacceptable toxicity.

      After completion of study treatment patients are followed up at 30 days and then every 8 or
      12 weeks.
    
  